Unknown

Dataset Information

0

Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.


ABSTRACT: Breast cancers over-express the human epidermal growth factor receptor 2 (HER2) in about 15% of patients. This transmembrane tyrosine kinase receptor activates downstream signaling pathways and leads to proliferation of cancer cells. Trastuzumab, an anti-HER2 monoclonal antibody, improves outcome in women with early and metastatic breast cancer. Resistance to trastuzumab involves the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway, truncation of the Her2 receptor or lack of immune response. The last decade has seen major advances in strategies to overcome resistance to trastuzumab. This includes the development of antibody-drug conjugates, dual HER2 inhibition strategies, inhibition of PI3K/mTOR pathway and development of modulators of immune checkpoints.

SUBMITTER: Lavaud P 

PROVIDER: S-EPMC4243818 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2009-01-01 | S-EPMC2787848 | BioStudies
2011-01-01 | S-EPMC3157979 | BioStudies
2017-01-01 | S-EPMC5495871 | BioStudies
2019-01-01 | S-EPMC6626398 | BioStudies
2020-01-01 | S-EPMC7072407 | BioStudies
2013-01-01 | S-EPMC3563710 | BioStudies
1000-01-01 | S-EPMC4134494 | BioStudies
2008-01-01 | S-EPMC2546920 | BioStudies
2018-01-01 | S-EPMC6192610 | BioStudies
2020-01-01 | S-EPMC7293079 | BioStudies